We generated FLT3 expressing BCR::ABL1 TKI-resistant CML cells and enrolled phase-specific CML patient cohort to obtain unpaired and paired serial specimens and verify the role of FLT3 signaling in BP-CML patients. This evidence concerns the gene FLT3 and chronic myelogenous leukemia, BCR-ABL1 positive.